Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Control Bionics (ASX:CBL), an assistive communication technology company, is integrating Apple technology. In November 2025, NorthStar Impact Funds reported Control Bionics announced it is integrating Apple's brain-computer interface protocol into its NeuroNode product lines, which could expand access and functionality for users with severe disabilities. Control Bionics operates in the Healthcare sector within the Healthcare Equipment and Supplies industry, and Thesis Tracker has captured 1 comment from 1 fund manager, NorthStar Impact Funds. Founded in 2005 and headquartered in Sydney, Control Bionics designs, manufactures and sells NeuroNode, a wireless wearable electromyography device that allows people with severe physical disabilities such as motor neurone disease and cerebral palsy to communicate and control computers and devices using small muscle signals, serving users in Australia, the US and Japan.
Company figures as of 15 Oct 2026. For information only.
Fund managers including NorthStar Impact Funds have invested in Control Bionics Ltd (ASX:CBL).
NorthStar highlights the integration of Apple's brain-computer interface protocol into NeuroNode, which could expand its reach and functionality.
The available commentary does not set out specific risks, though Control Bionics is a small company that relies on reimbursement and funding to grow.
Control Bionics Ltd. designs, manufactures and sells wireless wearable electromyography (EMG)-based augmentative and alternative communication (AAC) technology. Its segments are Australia, US, International, R&D and Corporate. The Australia segment covers sales of Trilogy units and components in Australia. The US segment covers manufacture and sales of Trilogy units and components in North America. The International segment supports new operating segments. The R&D segment covers research activities for the Group’s products. The Corporate segment provides support, regulatory and infrastructure activities.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.